To provide additional evidence to guide treatment choices for ALK -rearranged NSCLC patients, we conducted a Bayesian network meta-analysis to comprehensively integrate all available direct and indirect evidence with a well-designed and comparative synthesis. The gene discussed is ALK; the disease is non-small cell lung carcinoma.